| 0.7 0 (0%) | 09-18 15:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.91 |
1-year : | 1.03 |
| Resists | First : | 0.77 |
Second : | 0.88 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.6 |
Second : | 0.49 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.74 |
| MA(100) : | 0.49 |
MA(250) : | 0.58 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.9 |
D(3) : | 54.2 |
| RSI | RSI(14): 48.7 | |||
| 52-week | High : | 1.01 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CYAN ] has closed above bottom band by 17.1%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Tue, 17 Sep 2024
Cyanotech director Michael Davis buys $8,200 in company stock - Investing.com
Wed, 11 Sep 2024
Cyanotech executive Michael A. Davis buys shares worth $8,350 - Investing.com
Tue, 10 Sep 2024
Cyanotech executive buys $8,400 in company stock - Investing.com
Thu, 05 Sep 2024
Cyanotech director Michael Davis buys shares worth $8,200 - Investing.com
Mon, 12 Aug 2024
$1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying - Benzinga
Wed, 07 Aug 2024
Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Consumer Defensive
|
|
|
Industry:
Packaged Foods
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 38 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.52 |
| Profit Margin | -21.5 % |
| Operating Margin | -17.7 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 14.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.36 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0.2 |
| Price to Cash Flow | 12.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|